CN113679711A - Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation - Google Patents
Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation Download PDFInfo
- Publication number
- CN113679711A CN113679711A CN202111126144.8A CN202111126144A CN113679711A CN 113679711 A CN113679711 A CN 113679711A CN 202111126144 A CN202111126144 A CN 202111126144A CN 113679711 A CN113679711 A CN 113679711A
- Authority
- CN
- China
- Prior art keywords
- pancreatic cancer
- fisetin
- preparation
- proliferation
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 title claims abstract description 100
- 235000011990 fisetin Nutrition 0.000 title claims abstract description 50
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 47
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 47
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 47
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 47
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 27
- 230000035755 proliferation Effects 0.000 title claims abstract description 26
- 230000005764 inhibitory process Effects 0.000 title description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 108050006400 Cyclin Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012447 xenograft mouse model Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compound Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention firstly provides a new application of fisetin, namely an application in preparing a product for inhibiting pancreatic cancer cells or mouse pancreatic cancer tumor proliferation. In still another aspect, the present invention provides a preparation for inhibiting pancreatic cancer cell or mouse pancreatic cancer tumor proliferation, wherein the preparation comprises fisetin in a pharmacologically effective concentration. The invention discovers that fisetin can inhibit proliferation of pancreatic cancer cells and mouse pancreatic cancer tumors, and fisetin can be used for preparing a new medicine for treating pancreatic cancer.
Description
Technical Field
The invention belongs to the technical field of preparation of pancreatic cancer treatment medicines, and particularly relates to application of a traditional Chinese medicine small-molecule compound Fisetin (Fisetin) in inhibition of proliferation of pancreatic cancer cells and pancreatic cancer tumors of mice.
Background
Pancreatic cancer (PDAC), one of the most aggressive tumors in the digestive system that is common in the clinic, has a very poor prognosis due to its specific anatomical location and tumor biological behavior, and has a five-year survival rate that is penultimate in the persistence of all tumors, much lower than that of other tumors. Nowadays, the application of auxiliary chemotherapy, radiotherapy, immunotherapy, targeted therapy and other means in pancreatic cancer patients is increasingly common, and although the overall survival time of the patients is prolonged to a certain extent, the treatment effect is very limited. Therefore, new therapeutic approaches are urgently needed.
In recent years, with the continuous and deep research of traditional Chinese medicine treatment in the tumor field, the modern new traditional Chinese medicine preparation makes better progress in the clinical treatment process of tumor patients. The traditional Chinese medicine is improved into the Chinese patent medicine, so that the situations of complicated treatment application and the like in the traditional treatment process can be well avoided. Therefore, the screening of the traditional Chinese medicine small molecular compound for effectively inhibiting the pancreatic cancer proliferation and the deep research of the molecular mechanism of the effect of the compound have important significance for the clinical treatment of pancreatic cancer and the research and development of new chemotherapy schemes, and also have excellent clinical transformation and application prospects.
Disclosure of Invention
The invention aims to provide application of fisetin in inhibition of proliferation of pancreatic cancer cells and mouse pancreatic cancer tumors, namely fisetin is used for inhibiting proliferation of pancreatic cancer cells and mouse pancreatic cancer tumors, so that the defects of the existing pancreatic cancer treatment method are overcome.
The invention firstly provides a new application of fisetin, namely an application in preparing a product for inhibiting pancreatic cancer cells or mouse pancreatic cancer tumor proliferation.
In yet another aspect, the present invention provides a preparation for inhibiting pancreatic cancer cell or mouse pancreatic cancer tumor proliferation, wherein the preparation comprises fisetin in a pharmacologically effective concentration;
the pharmacological effective concentration is not lower than 50 mu M;
furthermore, the pharmacological effective concentration is 80-400 mu M;
the product is a liquid product;
as a specific liquid preparation, fisetin is added to a medium for culturing pancreatic cancer cells;
wherein the added concentration of fisetin in the culture medium is 80-400. mu.M;
another preparation is DMSO solution added with fisetin, wherein the addition concentration of fisetin is 0.559-1.048 mmol/kg.
The invention discovers that fisetin can inhibit proliferation of pancreatic cancer cells and mouse pancreatic cancer tumors, and fisetin can be used for preparing a new medicine for treating pancreatic cancer.
Drawings
FIG. 1: graph of the effect of fisetin on pancreatic cancer cell (PANC-1) proliferation, wherein Panel A is the cell viability of PANC-1 cells measured by the CCK-8 assay. Cells were treated with fisetin (0, 25, 50, 100, 200 and 400 μ M) for 24 and 48 hours, respectively. The absorbance was measured at 450 nm. Data are presented as mean ± SD; p is less than or equal to 0.05, # P is less than or equal to 0.05, panel B is real-time cell analysis (RTCA) of pancreatic cancer PANC-1 cells. Cells were tested for cell growth using an xCELLigence RTCA DP instrument for 72 hours after treatment with fisetin (0-400. mu.M). Every 15 minutes, each point represents the average from three replicates with SD.
FIG. 2: graph of the effect of fisetin on tumor proliferation in mouse pancreatic cancer.
FIG. 3: graph of the effect of fisetin on proliferation-associated proteins of pancreatic cancer tumor tissue in mice.
FIG. 4: graph of the effect of fisetin on proteins associated with the growth and proliferation of PANC-1 cells.
Detailed Description
Fisetin (Fisetin) is a natural flavonoid compound, has wide sources, low price and easy obtainment, and has wide pharmacological activities of resisting inflammation, resisting oxidation, resisting blood coagulation, resisting thrombus, treating diabetic kidney injury and the like. However, the applicant found in the research that the proliferation capacity of PANC-1 was significantly inhibited after treating pancreatic cancer cell line PANC-1 with fisetin. The proliferation ability of pancreatic cancer tumors was also significantly inhibited by treating xenograft pancreatic cancer mice with fisetin, which contributed to the present invention.
The present invention will be described in detail with reference to examples below:
example 1: fisetin can inhibit pancreatic cancer cell (PANC-1) proliferation
1. CCK8 experiment
The PANC-1 cells are inoculated in a 96-well cell culture plate, the proper number of plated cells is selected, 100 mu L of cell suspension is added into each well, 5 repeated wells are cultured in an incubator at 37 ℃, fisetin (0, 25, 50, 100, 200 and 400 mu M) with different concentrations is added for treatment for 24 and 48 hours after the cells adhere to the wall, a serum-free culture medium is added into a culture medium of 10 percent CCK8 in a liquid changing mode, the cells are cultured for 2 hours in the incubator at 37 ℃, and the absorbance is detected at the wavelength of 450 nm.
As shown in FIG. 1A, the activity of PANC-1 cells was not significantly inhibited by fisetin at concentrations of 25. mu.M and 50. mu.M, but proliferation of PANC-1 cells was effectively inhibited by fisetin at levels of 100. mu.M, 200. mu.M and 400. mu.M.
2. Real-time cell analysis (RTCA)
PANC-1 cells were seeded in 96-well cell culture plates and then treated with fisetin (0-400 μ M) for 72 hours, cell growth was monitored using an xcelligene RTCA DP instrument, the system recorded impedance every 15 minutes, the x-axis of the image represents time after treatment, the y-axis reflects a logarithmic relationship consistent with cell number, and each point represents the average from three replicates with SD.
The results are shown in FIG. 1, where fisetin inhibits the proliferation of PANC-1 cells in a dose and time dependent manner.
Example 2: fisetin can inhibit tumor proliferation of pancreatic cancer in mice
1. Xenograft mouse model
Animal experiments were performed according to institutional guidelines for care and use of laboratory animals. 10 female BALB/c nude mice, 4 weeks old, were obtained from Shanghai laboratory animal center, Chinese academy of sciences. By injecting 1X 10 under 3% isoflurane anesthesia in mouse axilla6Luciferase-labeled PANC-1 cells (Luc-PANC-1) were used to construct a subcutaneous xenograft mouse model. The mice were divided into two groups of five mice each. Treatment groups mice were treated with 0.1mL Fisetin (1.048mmol/kg body weight) by intraperitoneal injection every other day. The formula for the tumor volume is 0.52X length X width2. Control group abdomen0.1mL of DMSO was injected intraperitoneally.
2. Bioluminescent imaging
Mice were anesthetized with 3% isoflurane and then injected intraperitoneally with 200 μ L (15mg/mL) of D-fluorescein. After 15 minutes, tumors were imaged using IVIS lumine Series III (Perkin Elmer, usa). Data are expressed as mean radiance (photons/sec/cm/steradian), which is a calibrated measurement of photon emission.
The results are shown in figure 2 and demonstrate that the tumor size in mice treated with fisetin is significantly reduced.
Example 3: fisetin can inhibit proliferation-related protein of mouse pancreatic cancer tissue
1. Tissue fixation
Fixing tissue with 4% paraformaldehyde solution, sequentially adding 70%, 80%, 90%, 95%, 100% ethanol for 30min, dehydrating and clearing xylene for 1h × 2 times, soaking in paraffin solution, embedding, slicing into 4 μm slices, placing on glass slide in water bath, and oven drying at 60 deg.C.
2. HE staining
Drying the paraffin sections overnight; dewaxing the xylene conventionally for 2 times and 5 min/time; eluting xylene with anhydrous ethanol for 2 times, 10 min/time; dewaxing in 95%, 90%, 85%, 80% and 75% ethanol for 5 min/time. Staining with hematoxylin for 5min, washing with running water for 2min, differentiating with 1% hydrochloric acid alcohol for several seconds, washing with running water, returning blue with dilute ammonia water for 30s, washing with running water for 1min, staining with eosin solution for 10min, and washing with running water for 30 s. Dehydrating with 75%, 80%, 95%, 100% alcohol for 1 min/time; the xylene is transparent for 2 times and 2 min/time; sealing the neutral resin, and baking in an oven at 60 ℃. The morphological changes of the cells were observed using optical microscope image acquisition.
3. Immunohistochemistry
Dewaxing in 100%, 95%, 90%, 80% and 70% ethanol for 10 min; rinsing with clear water, soaking in 3% H2O2 for 10min for hydration, adding 0.01M citrate buffer solution, heating in microwave oven for 3min, cooling to room temperature, and repeating twice. Washing twice with water, washing twice with PBS, wiping off surrounding liquid, adding 10% serum, sealing at 37 deg.C for 30 min. Wiping out surrounding serum, dripping PCNA primary antibody, standing at 4 ℃ overnight, and rewarming at room temperature for 1 h. PBS was washed three times, the surrounding PBS was wiped dry, secondary antibody was added dropwise, 30min at 37 ℃. PBS was washed three times, the surrounding PBS was wiped dry, 1% SABC was added dropwise, 30min at 37 ℃. PBS was washed three times, the surrounding PBS was wiped dry, and a color developing agent was added dropwise. Washing with clear water, and soaking in hematoxylin stain. Washing with clear water, and sequentially adding 70%, 80%, 90%, 95%, 100% ethanol and xylene for 2 min. The surrounding xylene was wiped dry, neutral resin was added dropwise, covered with a glass cover, and dried in a fume hood.
The experimental result is shown in figure 3, and the proliferation-related protein Proliferating Cell Nuclear Antigen (PCNA) in the tumors of the mice in the fisetin treatment group is remarkably reduced.
Example 4: protein related to inhibition of PANC-1 cell growth and proliferation by fisetin
1、Western blot
Pancreatic cancer PANC-1 cells were treated with fisetin and controls were treated with DMSO. Cells were harvested by spatula, centrifuged at 6000rpm for 3 minutes and the supernatant discarded. Adding lysis solution, performing ice lysis for 30min, performing centrifugation for 20min at 4 ℃ and 12000rpm, keeping supernatant, adjusting the concentration after the protein concentration is detected by the BCA kit, and adding 4 xSDS-PAGE loading buffer into the supernatant for mixing.
Preparing 10% SDS-PAGE separation gel according to the molecular size of the protein, pressing with deionized water, preparing 5% concentrated gel, inserting into a comb, coagulating, loading, and separating the protein by electrophoresis (constant pressure: concentrated gel 80V, separating gel 120V). The proteins were transferred onto a PVDF membrane activated with methanol by wet transfer (constant flow: 300mA) and blocked with a 5% skimmed milk solution for 1 h. Washing the membrane with TBST for 3 times, incubating the primary antibody diluent overnight at 4 deg.C, sucking out the primary antibody, washing the membrane with TBST for 3 times, incubating the secondary antibody diluent at room temperature for 1h, and developing with chemiluminescence apparatus.
Experimental results as shown in fig. 4, fisetin treatment reduced the expression of the cell growth and proliferation-related proteins PCNA, Ki67 and phosphorylated histone H3 (p-H3).
Claims (9)
1. The application of fisetin is application in preparing a product for inhibiting pancreatic cancer cells or mouse pancreatic cancer tumor proliferation.
2. A preparation for inhibiting pancreatic cancer cell or mouse pancreatic cancer tumor proliferation, wherein the preparation comprises fisetin at a pharmacologically effective concentration.
3. The article of claim 2, wherein the concentration of fisetin in the article is not less than 50 μ M.
4. The article of claim 2, wherein the concentration of fisetin in the article is from 80 to 400 μ M.
5. The article of any one of claims 2-4, wherein the article is a liquid article.
6. The preparation according to claim 5, wherein the liquid preparation is a culture medium for the culture of pancreatic cancer cells supplemented with fisetin.
7. The preparation of claim 6, wherein said fisetin is added at a concentration of 80-400 μ M.
8. The preparation of claim 5, wherein the liquid preparation is a DMSO solution to which fisetin is added.
9. The preparation of claim 8, wherein said fisetin is added at a concentration of 0.559 to 1.048 mmol/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126144.8A CN113679711A (en) | 2021-09-26 | 2021-09-26 | Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111126144.8A CN113679711A (en) | 2021-09-26 | 2021-09-26 | Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679711A true CN113679711A (en) | 2021-11-23 |
Family
ID=78587189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111126144.8A Pending CN113679711A (en) | 2021-09-26 | 2021-09-26 | Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679711A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120283322A1 (en) * | 2010-08-11 | 2012-11-08 | Azi Company Ltd. | Rhus Verniciflua Stokes Extract Having Increased Content Of Active Flavonoid Compound And Method For Preparing Same |
| US20210038667A1 (en) * | 2018-10-10 | 2021-02-11 | Medience Co.,Ltd | Method for preparing rhus verniciflua stokes extract containing increased fisetin content, and metastasis-inhibiting anticancer agent composition containing same |
-
2021
- 2021-09-26 CN CN202111126144.8A patent/CN113679711A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120283322A1 (en) * | 2010-08-11 | 2012-11-08 | Azi Company Ltd. | Rhus Verniciflua Stokes Extract Having Increased Content Of Active Flavonoid Compound And Method For Preparing Same |
| US20210038667A1 (en) * | 2018-10-10 | 2021-02-11 | Medience Co.,Ltd | Method for preparing rhus verniciflua stokes extract containing increased fisetin content, and metastasis-inhibiting anticancer agent composition containing same |
Non-Patent Citations (1)
| Title |
|---|
| DING ET AL.: "Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation", CELL DEATH AND DISEASE, vol. 11, no. 893, 22 October 2020 (2020-10-22), pages 1 - 17 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103212071B (en) | Stem cell fusion model of carcinogenesis | |
| TWI746772B (en) | Use of umbilical mesenchymal stem cells for treating pulmonary fibrosis | |
| CN111420030A (en) | Application of FGF21 in preparation of medicine for treating colorectal cancer | |
| CN104211765B (en) | Polypeptide specifically binding with TRB3 protein, screening method, identification and application thereof | |
| François et al. | Long-term quantitative biodistribution and side effects of human mesenchymal stem cells (hMSCs) engraftment in NOD/SCID mice following irradiation | |
| CN107419004A (en) | LncRNA RP11 290F20.3 and its siRNA application | |
| CN108949984A (en) | Application of the gene DESI2 in three negative breast cancer diagnosis, prognosis evaluation and treatment | |
| Laface et al. | Chymase-positive Mast cells correlate with tumor angiogenesis: first report in pancreatic cancer patients. | |
| Xu et al. | The effects of in ovo nicotinamide riboside dose on broiler myogenesis | |
| CN114191540A (en) | Application of CTRP13 in preparing medicine for preventing and treating vascular and tumor diseases | |
| CN102552935B (en) | Use of hepatocyte nuclear factor-1alpha in treatment of chronic liver disease | |
| Chang et al. | From Hair to Colon: Hair Follicle-Derived MSCs Alleviate Pyroptosis in DSS-Induced Ulcerative Colitis by Releasing Exosomes in a Paracrine Manner | |
| CN113679711A (en) | Application of fisetin in inhibition of pancreatic cancer cell and mouse pancreatic cancer tumor proliferation | |
| CN105079785B (en) | Three domain protein 32(TRIM32) treating function and application in myocardial hypertrophy | |
| Lee et al. | Effects of stromal vascular fraction on breast cancer growth and fat engraftment in NOD/SCID mice | |
| CN110339198A (en) | Purposes of the JMJD3 inhibitor in the drug of preparation prevention and treatment pancreatitis | |
| CN109172557B (en) | Application of PPM-18 in inducing apoptosis of bladder cancer cells by activating intracellular reactive oxygen species | |
| CN110283825B (en) | SiRNA capable of knocking down SRC-1 gene expression and application thereof | |
| CN109661405A (en) | Tissue fibrosis prevention or treatment recombinant protein and comprising the protein tissue fibrosis prevention or therapeutic composition | |
| CN112641924A (en) | Medicine for treating thyroid cancer and preparation method and application thereof | |
| CN113679710A (en) | Application of fisetin in combination with gemcitabine in treatment of pancreatic cancer | |
| CN101392026B (en) | Polypeptide for preventing and treating fibrotic disease and liver cancer | |
| CN105168199A (en) | Application of curcumenol in preparing drug for performing targeted inhibiting on tumor cell EZH2 protein | |
| CN109528749A (en) | Purposes of the long-chain non-coding RNA-H19 in preparation treatment hypophysis tumor medicine | |
| CN113528520B (en) | Cyclic RNAhas _ circ _0000591 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |